vertex

Dendreon's Infectious Influence on Biotechs

One of Thursday's hardest-hit stocks was Dendreon, maker of the prostate cancer vaccine Provenge, which plunged 67% after reporting disappointing results. But, weirdly, Debdreon's disease seemed to infect the entire sector, dragging down companies with proven drugs. Are biotechs bargains right now?

The Five Best-Performing Biotech Stocks of 2011 -- So Far

Pharmaceuticals are facing big patent cliff problems this year, but several biotechnology stocks have been doing quite well: Their biologic drugs command high prices, tend become blockbusters, and -- perhaps most important -- are in far less danger from generic competition. Here are the big winners so far.

New Cystic Fibrosis Drug Treats the Disease's Cause

Vertex Pharmaceutical shares soared 15% Wednesday as Wall Street cheered the results of a late-stage study of its new cystic fibrosis drug, an experimental treatment that targets the underlying cause of the disease rather than just its symptoms.

World Drug Sales to Hit $880 Billion in 2011

Global pharmaceutical sales are expected to grow by 5% to 7% in 2011 to around $880 billion, thanks to robust growth in emerging markets, especially China, as well as new innovative treatments, and despite patent expirations and budget pressures in the developed world.

State sales taxes continue to rise

If you flip on the news or thumb through a newspaper these days, it's no secret that the federal government is facing a mounting deficit. Spending...